Compare AU
Compare DRUG vs. SEMI
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Global Healthcare Currency Hedged ETF (DRUG) and the Global X Semiconductor ETF (SEMI). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | SEMI | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 59 | 523 |
Median incremental investment | $920.50 | $843.58 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,988.48 | $2,064.00 |
Average age group | 26 - 35 | > 35 |
Key Summary
DRUG | SEMI | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | The Global X Semiconductor ETF (SEMI) aims to mimic the performance of the Solactive Global Semiconductor 30 Index prior to incorporating taxes, fees, and expenses. |
Top 3 holdings | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) | Broadcom Inc (11.78 %) Taiwan Semiconductor Manufacturing Co Ltd (11.51 %) NVIDIA Corp (9.90 %) |
Top 3 industries | Other (75.15 %) Communication Services (33.53 %) Health Care (24.75 %) | Information Technology (100.00 %) |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | United States (67.04 %) Taiwan (14.33 %) Netherlands (9.99 %) |
Management fee | 0.57 % | 0.57 % |
Key Summary
DRUG | SEMI | |
|---|---|---|
Issuer | BetaShares | Global X |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | Solactive Global Semiconductor 30 Index - USD - Benchmark TR Net |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.57 % |
Price | $8.25 | $17.33 |
Size | $183.750 million | $360.791 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.89 % | 1.07 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 30/08/2021 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | SEMI | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 59 | 523 |
Median incremental investment | $920.50 | $843.58 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,988.48 | $2,064.00 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
DRUG | SEMI | |
|---|---|---|
Pros |
| |
Cons |
|
DRUG | SEMI |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |